Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction

Susanne Jung1,2, Agnes Bosch1, Julie Kolwelter1,2

  • 1Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, Erlangen-Nuremberg, 91054, Germany.

ESC Heart Failure
|February 9, 2021
PubMed

Insights

Congestive heart failure (CHF) is linked to reduced kidney function and increased renal vascular resistance, particularly in heart failure with reduced ejection fraction (HFrEF). This highlights a significant cardiorenal interaction in patients with CHF.

Area of Science:

  • Cardiology
  • Nephrology
  • Renal Physiology

Background:

  • Congestive heart failure (CHF) frequently co-exists with impaired renal function, contributing to adverse cardiovascular outcomes.
  • Understanding the cardiorenal interplay is crucial for managing patients with CHF.

Purpose of the Study:

  • To assess renal and intraglomerular hemodynamics in subjects with CHF using a constant infusion clearance technique.
  • To compare hemodynamic parameters between patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) and healthy controls.

Main Methods:

  • Employed a constant infusion clearance technique to measure glomerular filtration rate (GFR), renal blood flow (RBF), and renal plasma flow (RPF).
  • Calculated intraglomerular hemodynamics, including afferent (RA) and efferent arteriolar resistances (RE) and intraglomerular pressure (Pglom).
  • Compared measurements between 27 HFpEF patients, 27 HFrEF patients, and 31 healthy controls.

Main Results:

  • CHF subjects exhibited lower GFR (68.1 mL/min/1.73 m²) and higher intraglomerular pressure (Pglom) compared to controls (83.6 mL/min/1.73 m²).
  • Total renal vascular resistance (RVR) was elevated in CHF patients, primarily due to increased afferent arteriolar resistance (RA).
  • HFrEF patients showed higher RA compared to HFpEF patients, and CHF severity correlated with reduced renal perfusion and increased RVR.

Conclusions:

  • Renal function (GFR) is reduced in both HFpEF and HFrEF, with a more pronounced effect in HFrEF.
  • Increased preglomerular, afferent arteriolar resistance is a key finding in CHF patients.
  • The study confirms a significant cardiorenal interaction in congestive heart failure.
Abstract

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
611
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
220
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
667
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
89
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.2K
Glomerular Filtration Rate and its Regulation01:28

Glomerular Filtration Rate and its Regulation

The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
4.3K